IP Library Granted Patent US 10,300,132
Granted Patent B2
US 10,300,132 · App. 14/655,041 · Granted May 28, 2019

Vaccines against hepatitis B virus

Inventors: Bertrand Victor Gilbert Georges (London, GB); Carlton Bradley Brown (London, GB)
Assignee: Altimmune UK Limited
A61K39/292A61K39/12A61K45/06C07K14/005C12N7/00A61K2039/55A61K2039/572A61K2039/58A61K2039/60A61K2039/70C12N2730/10122C12N2730/10134C12N2730/10171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,132
App. No.
14/655,041
Granted
May 28, 2019
Kind
B2
Abstract

A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Claims (9)

1. A fluorocarbon peptide construct comprising:

an immunogenic hepatitis B virus peptide sequence covalently attached to a vector for intracellular delivery of the peptide, wherein the vector comprises a chain comprising from 3 to 30 carbon atoms, at least one of which is substituted with fluorine, chlorine, bromine or iodine, and wherein the peptide is from 15 to 60 amino acids in length comprising at least 15 contiguous amino acids of the sequence shown in any one of SEQ ID NOs: 1 to 4 or SEQ ID No: 55 or of a sequence having at least 90% identity to one of the sequences shown in SEQ ID NOs: 1 to 4 or SEQ ID NO: 55, and which peptide comprises at least one CD8+ T-cell epitope and at least one CD4+ T-cell epitope; and wherein the peptide binds two or more HLA class I alleles.

2. The fluorocarbon peptide construct of claim 1 , wherein the peptide comprises at least 15 contiguous amino acids of the sequence shown in SEQ ID NO: 5, 6, 14 or 15.

3. The fluorocarbon peptide construct of claim 1 , wherein the peptide comprises one of the sequences shown in SEQ ID NOs: 24 to 38, or SEQ ID NO: 221 to 222, or a sequence having at least 90% identity to one of the sequences shown in SEQ ID NOs: 24 to 38, or SEQ ID NO: 221 to 222.

4. The fluorocarbon peptide construct of claim 1 , wherein the peptide comprises at least 15 contiguous amino acids of the sequence shown in SEQ ID NOs: 10, 11, 12, 13, 20, 21, 22, and 23.

5. The fluorocarbon peptide construct of claim 1 , wherein the peptide comprises at least 15 contiguous amino acids of the sequence shown in SEQ ID NO. 34 to 38 or 222.

6. The fluorocarbon peptide construct of claim 1 , wherein the peptide comprises a sequence shown in SEQ ID NOs: 24, 25, 28, 33, 34, 36, 37, 38 or 222.

7. The fluorocarbon peptide construct of claim 1 , wherein the vector comprises 3 to 30 carbon atoms.

8. The fluorocarbon peptide construct of claim 1 , comprising structure C m F n —C y H x (Sp)-R, where m=3 to 30, n<=2m+1, y=0 to 15, x <=2y, (m+y)=3-30 and Sp is an optional spacer moiety and R is the peptide.

Assignments (7)
CHANGE OF NAME Recorded Jul 11, 2018
From: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
To: VAXIN UK LIMITED
Reel/Frame 046529/0649 →
CHANGE OF NAME Recorded Jul 11, 2018
From: VAXIN UK LIMITED
To: ALTIMMUNE UK LIMITED
Reel/Frame 046529/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2018
From: BROWN, CARLTON BRADLEY; GEORGES, BERTRAND VICTOR GILBERT
To: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
Reel/Frame 046529/0341 →
CHANGE OF NAME Recorded Nov 10, 2015
From: VAXIN UK LIMITED
To: ALTIMMUNE UK LIMITED
Reel/Frame 037083/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: GEORGES, BERTRAND VICTOR GILBERT
To: VAXIN UK LIMITED
Reel/Frame 036975/0444 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2015
From: BROWN, CARLTON BRADLEY
To: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
Reel/Frame 037058/0232 →
CHANGE OF NAME Recorded Nov 6, 2015
From: IMMUNE TARGETING SYSTEMS (ITS) LIMITED
To: VAXIN UK LIMITED
Reel/Frame 037058/0855 →
Priority Claims (1)
GB 1223386.2 · Dec 24, 2012 · national
Continuity (1)
Related Publication 20160106830A1 · Apr 21, 2016
Cited By (1)
US 12,709,634